Nuclera and Cytiva Collaborate to Accelerate Characterization of Proteins for Drug Development
Proteins represent 95% of drug targets designed to combat disease. Rapid access to these proteins and understanding how they interact with drug candidates is essential for drug development. Typically, it takes months to obtain and characterize proteins, but Nuclera and Cytiva together have achieved production and characterization within five days. This achievement was showcased at industry conferences Discovery on Target and PEGS Europe, where Nuclera's eProtein Discovery System was used to produce Bruton's Tyrosine Kinase (BTK) and Vascular Endothelial Growth Factor (VEGF). These proteins were subsequently functionally characterized using Cytiva's Biacore SPR system.
Dr. Yvonne Tan, Associate Director of Product Management, Nuclera, commented: 'Collaborating with life science leader Cytiva supports Nuclera in our mission of improving human health. Through this collaboration, we have demonstrated eProtein Discovery's ability to produce clinically significant proteins that can be used in characterization experiments. Combining eProtein Discovery's capability to streamline protein production workflows with Cytiva's Biacore protein characterization systems open a whole new avenue for accelerating drug development.'
Anna Moberg, Senior Manager and Project Manager, Cytiva, added: 'The ability of Nuclera's eProtein Discovery to accelerate protein production and purification complements Cytiva's Biacore SPR technology by streamlining the upstream protein production process. We look forward to continuing our collaboration to further enhance the production of characterizable proteins for drug development.'
For more information about Nuclera's eProtein Discovery System, please visit:
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a day ago
- Yahoo
Intuitive Surgical, Inc. (ISRG): 'I Really Like' It, Says Jim Cramer
We recently published . Intuitive Surgical, Inc. (NASDAQ:ISRG) is one of the stocks Jim Cramer recently discussed. Intuitive Surgical, Inc. (NASDAQ:ISRG) is a market leader in the hot global medical robotics industry. Its shares have lost 5.5% year-to-date primarily due to weaker margin forecasts, the firm's warning that US trade tensions could lower global sales of its Da Vinci medical robots, and bearish analyst sentiments. Cramer's previous remarks about Intuitive Surgical, Inc. (NASDAQ:ISRG) have expressed optimism about the firm and its business prospects. He believes that the company has a global presence and continues to expand its product expertise by adding more procedures. This time, he continued to have faith in Intuitive Surgical, Inc. (NASDAQ:ISRG): 'ISRG I really like Intuitive.' Cramer discussed Intuitive Surgical, Inc. (NASDAQ:ISRG) in detail in April. Here's what he said: 'Eighth best performer of the Mad Money era is Intuitive Surgical, ISRG, the creator of the minimally invasive Da Vinci Robotic Surgical System. This is another name that we found early on. I first interviewed someone from the company back in July of 2005 when the stock was trading at a split-adjusted price of $5 and change. Copyright: nimon / 123RF Stock Photo Since then, we've watched this Intuitive Robotic Surgical system… spread across the globe, constantly improving along the way and adding more types of procedures that it could do. The company's now [a] $184 billion behemoth, and this stock has given you more than 10,000% gain since the show got started. I think this is as relevant as ever. Company just reported an excellent set of numbers last Tuesday. I'm proud to be a huge supporter of this.' While we acknowledge the potential of ISRG as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
2 days ago
- Yahoo
Interstellar Meteors Hit Earth All the Time but Still Elude Astronomers
Astronomers think small space rocks from beyond our solar system routinely strike Earth—but proving it isn't easy Aliens are visiting our solar system. Not little green men, sadly, but natural alien objects—cosmic bodies such as comets and asteroids born elsewhere in the galaxy that zip by the sun as they drift through the Milky Way. They're not so much visiting as just passing through. Though these objects were speculated to exist for a long time, we didn't know they were out there for sure until October 2017, when astronomers noticed a small body moving through space at exceptionally high speed. Observations over just a few nights showed it was moving far too quickly to be orbiting the sun and thus must have come from some other star. It was our first known interstellar visitor. [Sign up for Today in Science, a free daily newsletter] Eventually designated 1I/'Oumuamua, it was 30 million kilometers from Earth and already outward bound from the solar system when it was discovered, offering scant time for follow-up studies. But then, less than two years later, a second such object was found, also moving far faster than usual. 2I/Borisov turned out to be a comet very similar to those we're familiar with, except for its trajectory, which clearly showed it came from interstellar space. And now a third such alien body is barreling through the solar system: 3I/ATLAS, moving so rapidly its path is barely bent at all by the sun's gravity as it zooms past. In science, one is an anomaly and two might be coincidence, but three is a trend. Clearly, objects like this are passing by on the regular. Roughly speaking, there could be ones 100 meters in size or larger passing through the inner solar system at any time. Given their speed and intrinsic faintness, though, they're difficult to detect. We also know that when it comes to things such as asteroids and comets, nature tends to make many more smaller ones than bigger ones. In our own solar system, for example, only a couple of dozen main-belt asteroids are bigger than 200 km wide, but more than a million are 1 km across or larger. This generalization should hold for interstellar interlopers as well. For every kilometer-scale one that we see, there should be far more that are smaller. In fact, there could be millions of sand-grain-sized alien objects whizzing past us right now. And we already know that they're out there: in 2014 astronomers announced they had found seven grains of cosmic dust brought down to Earth from the Stardust space probe, which was designed to catch material ejected from a comet. Also, embedded in some meteorites that have hit Earth are tiny bits of material, called presolar grains, that are so old they actually formed around other stars. They got here after being blown across the void of space into the collapsing cloud of gas and dust that formed the sun and planets 4.6 billion years ago. Larger material could be ejected from an alien planetary system if it's given a gravitational assist when passing by a planet there, or it could be torn away from its parent star by another star passing closely to that system. So it seems certain interstellar jetsam would occasionally hit our planet. Earth is a small target, but with so many galactic bullets, you'd think some would actually find their way to our planetary bull's-eye. The problem is detecting them. Every day Earth is hit by very roughly 100 tons of locally grown interplanetary debris—material ejected from asteroids and comets native to our solar system—which translates into billions of tiny specks zipping across our sky daily. Detecting the tiny fraction that have an interstellar origin is tough. And the difficulty is not just in the sheer numbers. It's in tracing the trajectories of that small handful across the sky back up into space to calculate their orbits. When an object such as a planet or an asteroid orbits the sun, we say it's gravitationally bound to our star. That orbit in general is an ellipse, an oval shape. These can be defined mathematically, with the key factor being the eccentricity: how much the ellipse deviates form a circle. A perfect circle has an eccentricity of 0, and the higher the eccentricity, the more elliptical the orbit, up to a value of just under 1. An orbit with an eccentricity of 0.99, say, is extremely elongated; you might find that an object dropping down very close to the sun from the outer solar system has an eccentricity that high. It's possible to have an eccentricity higher than 1 as well. That kind of trajectory is called hyperbolic—named after the mathematical curve, not because it's exaggeratedly over-the-top—and an object on this path is not bound to the sun gravitationally. Once it's heading out, it's gone forever. It ain't coming back. This is how we know 'Oumuamua, Borisov and ATLAS are from interstellar space; each has an eccentricity greater than 1—'Oumuamua's is about 1.2 and Borisov's 3.4, which is quite high, but ATLAS has them both beat with an astonishing eccentricity of 6.2. That's extraordinarily high and also indicates it's hauling asteroid (or, more accurately, it's not comet back). Do we see any meteors with eccentricities like these? If the exact path of a meteoroid (the term for the solid bit that burns up in the air and becomes a meteor) through Earth's atmosphere can be determined, that can be backtracked up into space, allowing the object's trajectory, including its eccentricity, to be calculated. This can be done with multiple sky cameras set up in various locations; if a meteor streaks across their field of view, the multiple vantages can allow astronomers to triangulate on the rock and measure its path. There are quite a few such camera networks. It's actually difficult getting good enough data to determine solid orbits for meteoroids, though. Many do have eccentricities very close to 1; these likely come from long-period comets that originate out past Neptune. NASA's Jet Propulsion Laboratory maintains a database of bright fireballs—exceptionally luminous meteors—at the Center for Near-Earth Object Studies (CNEOS). The earliest recorded meteors in the database date back to 1988, so there is a rich hunting ground in the data. Are any of the meteors listed hyperbolic? Unfortunately, no. At least, not unambiguously—there have been false positives but nothing clear-cut. Additionally, a study from 2020 looked at 160,000 measurements by the Canadian Meteor Orbit Radar covering 7.5 years. The researchers found just five potential interstellar meteors. The results aren't quite statistically strong enough to claim detections for sure, but they're very compelling. What we need are more eyes on the sky, more meteor camera networks that can catch as many of these pieces of cosmic ejecta burning up in our atmosphere as possible. It's a numbers game: the more we see, the more likely we'll see some that are not from around here. The science would be, well, stellar: these meteors can tell us a lot about the environments around other stars, the ways they formed and perhaps even the stars they come from. We're getting physical samples from the greater galaxy for free. We should really try to catch them. Hat tip to planetary scientist Michele Bannister for the link to the CNEOS article. Solve the daily Crossword
Hamilton Spectator
2 days ago
- Hamilton Spectator
PharmAla Issues Q3 Financial Statements
TORONTO, July 25, 2025 (GLOBE NEWSWIRE) — PharmAla Biotech Holdings Inc. ('PharmAla' or the 'Company') (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased to have publicly filed its financial and operational results for the period ended May 31, 2025. All figures are reported in Canadian dollars. The Company's full set of unaudited condensed interim consolidated financial statements for the quarter and accompanying management's discussion and analysis can be accessed by visiting the Company's website at and its profile page on SEDAR+ at . 'The re-opening of PharmAla's domestic Canadian distribution has allowed us to execute as much volume in Q2 and Q3 as we did in all of the last fiscal year. The creation of our Prescriber's Portal has also allowed us to build a much closer relationship with our doctor customers, which we believe will serve us well moving forward,' said Nick Kadysh, CEO, PharmAla Biotech. 'As we move into the last quarter of Fiscal '24-25, we are incredibly pleased that a large shipment of LaNeo MDMA has arrived at our US distribution partner for delivery to a considerable group of clinical trial customers, most previously announced. PharmAla is also pleased to announce the completion of a manufacturing run in Australia for our 40mg LaNeo Capsules. These capsules were jointly manufactured for both Cortexa's use within Australia and PharmAla's use worldwide, and our improved manufacturing process should yield operational benefits well into the future.' Financial Highlights: 'Over the past quarter, our team has made exciting progress to ensure a reliable supply of pharmaceutical product for both researchers in clinical trials and patients in need of treatment,' said Will Avery, CFO, PharmAla Biotech. 'Our Prescriber Platform continues to empower physicians to access the MDMA and provide treatment for their patients and we look forward to additional clinical trial fulfillment to US and international customers in the near term, unburdened by cross-border trade issues.' About PharmAla PharmAla Biotech Holdings Inc. (CSE: MDMA) (OTCQB: MDXXF) is a biotechnology company focused on the research, development, and manufacturing of MDXX class molecules, including MDMA. PharmAla was founded with a dual focus: alleviating the global backlog of generic, clinical-grade MDMA to enable clinical trials as well as commercial sales in selected jurisdictions, and to develop novel drugs in the same class. PharmAla is the only company currently provisioning clinical-grade MDMA for patient treatments outside of clinical trials. PharmAla's research and development unit has completed proof-of-concept research into several IP families, including ALA-002, its lead drug candidate. PharmAla is a 'regulatory first' organization, formed under the principle that true success in the psychedelics industry will only be achieved through excellent relationships with regulators. For more information, please contact: Nicholas Kadysh Chief Executive Officer PharmAla Biotech Holdings Inc. Email: press@ Phone: 1-855-444-6362 Website: Neither the CSE nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release. Cautionary Note Regarding Forward-Looking Statements This press release contains 'forward-looking statements' within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking statements. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as 'plans', 'strategy', 'expects' or 'does not expect', 'intends', 'continues', 'anticipates' or 'does not anticipate', or 'believes', or variations of such words and phrases or may contain statements that certain actions, events or results 'will be taken', 'will launch' or 'will be launching', 'will include', 'will allow', 'will be made' 'will continue', 'will occur' or 'will be achieved'. We direct readers to refer to the 'Caution Regarding Forward-Looking Statements' contained within the Company's management's discussion and analysis for the period ended May 31, 2025, as filed on Sedar+ . Readers are cautioned to not place undue reliance on forward-looking information. Actual results and developments may differ materially from those contemplated by these statements. Although the Company believes that the expectations reflected in these statements are reasonable, such statements are based on expectations, factors, and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond the Company's control, including but not limited to the risk factors discussed in the Company's management's discussion and analysis, and elsewhere in this press release, as such factors may be further updated from time to time in our periodic filings, available at , which factors are incorporated herein by reference. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement and reflect the Company's expectations as of the date hereof and are subject to change thereafter. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events or results, or otherwise, or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the United States Securities Act of 1933, as amended, and applicable state securities laws.
